 |
|
Positive clinical trial results of investigational thrombocytopenia agent
December 13, 2006AKR-501 is a promising member of a new class of agents called, "TPO receptor agonists" that is now in Phase II clinical development. It is an investigational orally administered drug being developed by AkaRx, Inc. intended to mimic the biologic effect of thrombopoietin, a growth factor that stimulates production of platelets.
At the American Society of Hematology meeting, results from two Phase I clinical research trials were presented. These data in healthy volunteers showed that AKR-501 produced a 50% increase or greater over the baseline platelet count. AKR-501 is the first oral drug in its class to show these platelet increases with a single dose. In the single dose study this was achieved at the 100 mg dose. In all volunteers given multiple doses of either 10 mg or 20 mg for 10 - 14 days a platelet effect was observed where increases were at least 50% over baseline.
The unmet medical need for AKR-501 is that there is no approved agent to specifically stimulate megakaryocytes to produce platelets to treat thrombocytopenia in the same way that there are products available to stimulate production of red and white blood cells. Severe thrombocytopenia is currently managed in some settings with platelet transfusions. However, this temporary solution in not suitable for long-term use in chronic settings and is often associated with serious complications when used in acute situations. AKR-501 imitates the body's mechanism for stimulating platelet production by mimicking the action of thrombopoietin-the growth factor that modulates this process.
"AKR-501 is a very promising candidate for use in the prevention and treatment of thrombocytopenia in a host of diseases, among them, ITP, Chemotherapy Induced Thrombocytopenia, and Hepatitis C associated thrombocytopenia," said Robert E. Desjardins, MD, President and CEO of the drug development company, AkaRx. "These are the first clinical results of AKR-501 that show that it may be a safe thrombopoietic agent with an impressive ability to stimulate platelet production. This class may be a real breakthrough for patients. These results for AKR-501 give us confidence to envision a very broad clinical development program across the world for this compound that appears to have great medical and commercial potential."
thrombocytopenia agent
"AKR-501 is a very promising candidate for use in the prevention and treatment of thrombocytopenia in a host of diseases, among them, ITP, Chemotherapy Induced Thrombocytopenia, and Hepatitis C associated thrombocytopenia," said Robert E. Desjardins, MD, President and CEO of the drug development company, AkaRx. "These are the first clinical results of AKR-501 that show that it may be a safe thrombopoietic agent with an impressive ability to stimulate platelet production. This class may be a real breakthrough for patients. These results for AKR-501 give us confidence to envision a very broad clinical development program across the world for this compound that appears to have great medical and commercial potential."
thrombocytopenia agent
Thrombocytopenia Current Events and Thrombocytopenia News RSSLancet Study Supports New, Highly Effective Treatment for Blood Disorder
Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health.
Promising results from 2 trials highlighting pomalidomide presented at ASH
Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis.
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse.
Novel therapeutic approaches may improve patient outcomes in several platelet disorders
Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood.
Clinical study shows biological and clinical activity in relapsed leukemia patients
Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).
Ireland Cancer Center researchers advance stem cell gene therapy
Ireland Cancer Center of University Hospitals Case Medical Center researchers have recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects.
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.
Potentially Safe and Effective Therapy Revealed for Patients with Protein-Losing Enteropathy
Researchers at the Burnham Institute for Medical Research (Burnham Institute) have developed the first model to study intestinal protein leakage in mice, allowing the team to control and replicate both genetic deficiencies and environmental damages in an in vivo setting.
New study finds antibiotic vancomycin may trigger dangerously low platelet count
The antibiotic vancomycin often used in intensive care units is considered the drug of choice for the treatment of staphylococci (staph) infections that are resistant to most other antibiotics.
No benefit to increasing dose intensity of chemotherapy in osteosarcoma, study finds
A dose-intensive regimen of the chemotherapy drugs cisplatin and doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcoma, according to results from a randomized trial in the January 17 issue of the Journal of the National Cancer Institute.
More Thrombocytopenia Current Events and Thrombocytopenia News Articles
 |
Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology) by Theodore E. Warkentin (Editor), Andreas Greinacher (Editor) Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians. This Fourth Edition reinforces its standing as the leading guide to the accurate diagnosis and management of HIT by identifying key signs and symptoms of this disorder and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage these critical circumstances. Intended for those requiring an expert source of guidance for the quick detection and control of HIT, this reference: contains new chapters on novel pharmacotherapies, recent drug approvals, current dosing guidelines, and... |
 |
Canine I.T.P. Solution by Healthy Pet Solutions I.T.P. Solution is designed to help with low platelet problems. It is effective in healthy spleen support and promoting healthy platelet production from bone marrow. The I.T.P. Solution works to resolve the low platelet problem over time. Initially a higher dosage of the I.T.P. Solution may be needed to jump start platelet production. A maintenance dosage may be necessary after healthy platelet levles are achieved. |
 |
Blood Well Special (150 grams Powder) - Concentrated Herbal Blend - Dietary Supplement by Get Well Natural Get Well Naturals Blood Well Special Tea is an exclusive herbal dietary supplement that combines select natural ingredients from both Blood Well and Restore Immune II in an easy to take powder form and is recommended for children or adults who cant swallow pills. This exclusive formula was specifically designed to promote healthy platelets and healthy blood coagulation while promoting normal immune function.* For those with either Immune or Idiopathic Thrombocytopenic Purpura (I.T.P.), Dr. Ba Hoang's medical and immunological research for his PhD on I.T.P. has offered unique insights into this condition.* The herbs contained in Blood Well Special were carefully chosen based on his research in this field. *The FDA has not evaluated these statements. Our statements and products are not... |
 |
Thrombocytopenia Toolkit - Comprehensive Medical Encyclopedia with Treatment Options, Clinical Data, and Practical Information (Two CD-ROM Set) by U.S. Government (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on the subject of thrombocytopenia, a condition in which the blood has a low number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through blood vessels and stick together (clot) to stop any bleeding that could happen if a blood vessel is damaged. Platelets also are called thrombocytes, because a clot also is called a thrombus. When blood has a low number of platelets, mild to serious bleeding can occur. This bleeding can happen inside the body (internal bleeding) or on the skin. A normal platelet count is 150,000 to 450,000 platelets per microliter of blood. A count of less than... |
 |
Alloimmune Disorders of Pregnancy: Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn by Andrew Hadley (Editor), Peter Soothill (Editor) The effective prevention, diagnosis, and management of alloimmune cytopenias has become a team effort involving hematologists, obstetricians, pediatricians, immunologists, laboratory technicians, midwives, and research scientists. This book has been written by experts in their respective fields to bring together the issues of pathogenesis, epidemiology, prevention, diagnosis, and clinical management. This comprehensive but accessible account is extensively cross-referenced to emphasize the links between pathogenesis and clinical sequels, between epidemiology and the rationale for screening programs, and between diagnosis and therapeutic intervention. |
|
Gale Encyclopedia of Medicine: Thrombocytopenia by Dominic De Bellis PhD (Author) The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major topics. Disease/disorder articles typically cover definition; description; causes and symptoms; diagnosis; treatments; prevention; and more. Test/treatment articles typically cover definition; purposes; precautions; preparation; risks; normal and abnormal results; and much more. This second edition includes more than 200 new entries, 300 updated entries, approximately 650 color... | |
|
Idiopathic thrombocytopenia purpura: An entry from Thomson Gale's Gale Encyclopedia of Children's Health: Infancy through Adolescence by L. Culvert (Author), Rebecca, PhD Frey (Author) Avoiding hard-to-understand medical jargon, the four-volume “Gale Encyclopedia of Children’s Health” uses language that parents can understand, while still providing enough depth to benefit today's health science students. The set provides in-depth coverage of pediatric diseases and disorders, along with issues related to physical and cognitive/behavioral development. | |
|
21st Century Complete Medical Guide to Bleeding Disorders, Thrombocytopenia, von Willebrand Disease (VWD), Idiopathic Thrombocytopenic Purpura (ITP), Authoritative ... Information for Patients and Physicians by PM Medical Health News (Author) This up-to-date electronic book on CD-ROM provides the best collection available anywhere of official Federal government information and documents on the subject of bleeding disorders, thrombocytopenia, idiopathic thrombocytopenic purpura, and von Willebrand disease. This CD-ROM uses next-generation search technology that allows complete indexing and makes all files on the disc fully searchable. For patients, practical information is provided in clearly written patient education documents. For medical professionals, doctor reference tools and texts have detailed technical information and clinical background material. A bleeding disorder exists when it is hard for a person to stop bleeding. When a person bleeds, the blood clots, stopping the bleeding. The clotting process, also... | |
|
Heparin-Induced Thrombocytopenia by Samuel Z. (Editor in Chief) Goldhaber (Author) | |
 |
21st Century Ultimate Medical Guide to Thrombocytopenia - Authoritative, Practical Clinical Information for Physicians and Patients (Two CD-ROM Set) by PM Medical Health News (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on the subject of thrombocytopenia, a condition in which the blood has a low number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through blood vessels and stick together (clot) to stop any bleeding that could happen if a blood vessel is damaged. Platelets also are called thrombocytes, because a clot also is called a thrombus. When blood has a low number of platelets, mild to serious bleeding can occur. This bleeding can happen inside the body (internal bleeding) or on the skin. A normal platelet count is 150,000 to 450,000 platelets per microliter of blood. A count of less than... |
| © 2009 BrightSurf.com |